Skip to main content Skip to main navigation menu Skip to site footer

Status gizi anak dengan lupus eritematosus sistemik saat diagnosis dan tiga bulan terapi siklofosfamid

  • William Grandinata Soeseno ,
  • Ketut Dewi Kumara Wati ,
  • I Gusti Ayu Putu Eka Pratiwi ,

Abstract

Background: Malnutrition in children often occurs in chronic diseases that require long-term management and hospital care. Childhood-onset systemic lupus erythematosus (cSLE) is a chronic disease that requires long-term hospitalization, accompanied by difficulty eating or nausea after cyclophosphamide therapy, thereby risking threatening nutritional status. This study evaluated differences in cSLE nutritional status at diagnosis and three months of cyclophosphamide therapy.

Methods: Cross-sectional comparative study involving cSLE patients from 2015 to 2020. The mean body weight/ideal body weight ratio at diagnosis was then compared with the mean body weight/ideal body weight ratio at three months of cyclophosphamide therapy. Data analysis used a paired T-test via SPSS ver.22, where the p-value was considered significant if <0,05.

Results: This study included 88 cSLE patients, 16 boys (18,2%) and 72 girls (81,8%). Nutritional status at the time of diagnosis consisted of good nutrition 37 (42%), mild malnutrition 11 (12,5%), moderate malnutrition 12 (13.6%), severe malnutrition 4 (4,5%), overweight 8 (9,1%), and obesity 16 (18,2%). The nutritional status of children at three months of cyclophosphamide therapy consisted of good nutrition 36 (40,9%), mild malnutrition 13 (14.8%), moderate malnutrition 12 (13.6%), severe malnutrition 2 (2.3%), overweight 15 (17%), and obesity 10 (11,4%). The mean weight/ideal body weight ratio at diagnosis and three months of cyclophosphamide was 101,30 ± 21,53 and 100,38 ± 19,82, respectively, with an average difference of 0,92 ± 1,71 (95% CI 0,039-1,801; p=0,04).

Conclusion: Although statistically significant, the differences in nutritional status at diagnosis and three months of cyclophosphamide did not have important clinical implications.

 

 

Latar Belakang: Malnutrisi pada anak sering terjadi pada penyakit kronis yang membutuhkan manajemen jangka panjang dan perawatan rumah sakit. Lupus eritematosus sistemik onset masa kanak atau childhood-onset systemic lupus erythematosus (cSLE) adalah penyakit kronis yang membutuhkan rawat inap jangka panjang, disertai kesulitan makan atau mual setelah terapi siklofosfamid, sehingga berisiko mengancam status gizi. Studi ini bertujuan untuk mengevaluasi perbedaan status gizi cSLE pada saat diagnosis dan tiga bulan terapi siklofosfamid.

Metode: Studi komparatif potong lintang yang melibatkan pasien cSLE dari periode tahun 2015 hingga 2020. Parameter berupa rata-rata rasio berat badan/berat badan ideal saat diagnosis, selanjutnya dibandingkan dengan rata-rata rasio berat badan/berat badan ideal pada tiga bulan terapi siklofosfamid. Analisis data menggunakan uji-T berpasangan melalui SPSS ver.22, dimana nilai p dianggap signifikan jika <0,05.

Hasil: Studi ini melibatkan 88 pasien cSLE; dengan anak laki-laki sebanyak 16 pasien (18,2%) dan perempuan sebanyak 72 pasien (81,8%). Status gizi pada saat diagnosis terdiri atas gizi baik 37 (42%), malnutrisi ringan 11 (12,5%), malnutrisi sedang 12 (13,6%), malnutrisi berat 4 (4,5%), kelebihan berat badan 8 (9,1%), dan obesitas 16 (18,2%). Status gizi anak pada tiga bulan terapi siklofosfamid terdiri atas gizi baik 36 (40,9%), malnutrisi ringan 13 (14,8%), malnutrisi sedang 12 (13,6%), malnutrisi berat 2 (2,3%), kelebihan berat badan 15 (17%), dan obesitas 10 (11,4%). Rata-rata rasio berat badan/berat badan ideal saat diagnosis dan tiga bulan siklofosfamid masing-masing adalah 101,30 ± 21,53 dan 100,38 ± 19,82; dengan perbedaan rata-rata 0,92±1,71 (IK95% 0,039-1,801; p=0,04).

Simpulan. Walaupun terdapat perbedaan statistik yang signifikan, perbedaan status gizi saat diagnosis dan tiga bulan siklofosfamid tidak memiliki implikasi klinis yang signifikan.

References

  1. Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002 Aug;28(3):561–77, vi–vii.
  2. Klack K, Bonfa E, Borba Neto EF. Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol. 2012;52(3):384–408.
  3. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345–64.
  4. Mok CC, To CH, Ma KM. Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. Lupus. 2008 Nov;17(11):1018–22.
  5. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008 Feb;58(2):556–62.
  6. Souza L, Calzza J, Cassol E, Xavier RM, Monticielo O. AB0469 evolution of anthropometric profile and habit food after 10 years in systemic lupus erythematosus patients. Ann Rheum Dis. 2016;75:1001.
  7. Jansen H, Postma A, Stolk RP, Kamps WA. Chronic diseases and obesity : increased energy intake or decreased physical activity. Support care Cent. 2009;17(1):103–6.
  8. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008 Apr;152(4):550–6.
  9. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am. 2000 May;26(2):199–213, v.
  10. Arkachaisri T. Pediatric rheumatology in Southeast Asia: insights from the Singapore experience. Curr Rheumatol Rep. 2011 Apr;13(2):117–22.
  11. Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev. 2010 Mar;9(5):A267-70.
  12. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010 Sep;6(9):538–46.
  13. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008 Dec;29(24):2959–71.
  14. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008 Apr;17(4):314–22.
  15. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev. 2017 Jun;30(1):118–37.
  16. Pluchinotta FR, Schiavo B, Vittadello F, Martini G, Perilongo G, Zulian F. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus. 2007;16(8):550–5.
  17. Huang JL, Yeh KW, Yao TC, Huang YL, Chung HT, Ou LS, et al. Pediatric lupus in Asia. Lupus. 2010 Oct;19(12):1414–8.
  18. Behiry ME, Salem MR, Alnaggar AR. Assessment of nutritional status and disease activity level in Systemic Lupus Erythematosus patients at a tertiary care hospital. Rev Colomb Reumatol (English Ed. 2019;26(2):97–104.
  19. Hadi Kartiko B, Milas Siswanto F, Purwata TE. Mesenchymal stem cell (MSC) as a potential cell therapy for immune related disease. Bali Med J. 2017;6(1):38.
  20. Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: A nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol. 2004;22(6):776–80.
  21. Borges MC, dos Santos F de MM, Telles RW, Lanna CCD, Correia MITD. Nutritional status and food intake in patients with systemic lupus erythematosus. Nutrition. 2012;28(11–12):1098–103.
  22. dos Santos F de MM, Borges MC, Correia MITD, Telles RW, Lanna CCD. Assessment of nutritional status and physical activity in systemic lupus erythematosus patients. Rev Bras Reumatol. 2010;50(6):631–8.
  23. Suntoko B, Hadisaputro S, Kalim H, Hadi S, Aditia F. A double-blind, randomized controlled trial of hydroxychloroquine for cognitive dysfunction and antibody biomarkers in systemic lupus erythematosus patients. Bali Med J. 2023;12(2):2264–70.
  24. Chen Z, Li M-T, Xu D, Yang H, Li J, Zhao J-L, et al. Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center. PLoS One. 2014;9(12):e114684.
  25. Mina R, Brunner HI. Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010 Feb;36(1):53–80, vii–viii.

How to Cite

Soeseno, W. G. ., Wati, K. D. K., & Pratiwi, I. G. A. P. E. . (2024). Status gizi anak dengan lupus eritematosus sistemik saat diagnosis dan tiga bulan terapi siklofosfamid. Medicina, 55(1), 73–77. https://doi.org/10.15562/medicina.v55i1.1297

HTML
6

Total
3

Share

Search Panel

William Grandinata Soeseno
Google Scholar
Pubmed
Medicina Journal


Ketut Dewi Kumara Wati
Google Scholar
Pubmed
Medicina Journal


I Gusti Ayu Putu Eka Pratiwi
Google Scholar
Pubmed
Medicina Journal